کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6185129 | 1254355 | 2014 | 5 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
SGO guidance document for clinical trial designs in ovarian cancer: A changing paradigm
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
زنان، زایمان و بهداشت زنان
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
There has been an evolution in the acceptance of surrogate endpoints depending upon the clinical setting in ovarian cancer. While overall survival (OS) remains the most objective clinical trial endpoint, there is now realization that demanding OS as the primary endpoint has many obstacles. Ovarian cancer is a heterogeneous disease that is now divided by histologic subtypes. Future registration strategies will need to address disease heterogeneity. The exploration of currently acceptable clinical trial endpoints and alternative regulatory strategies will hopefully stimulate interest in novel drug development for patients with ovarian cancer.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Gynecologic Oncology - Volume 135, Issue 1, October 2014, Pages 3-7
Journal: Gynecologic Oncology - Volume 135, Issue 1, October 2014, Pages 3-7
نویسندگان
Thomas J. Herzog, Ronald D. Alvarez, Angeles Secord, Barbara A. Goff, Robert S. Mannel, Bradley J. Monk, Robert L. Coleman,